3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
7
Terminated
3
Withdrawn
1
Unknown
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
1296
Carcinoma, Non-Small-Cell Lung
793
Neoplasms
787
Colorectal Neoplasms
762
Stomach Neoplasms
588
Carcinoma, Hepatocellular
581
Prostatic Neoplasms
514
Lung Neoplasms
466
Pancreatic Neoplasms
421
Rectal Neoplasms
336
Recurrence
315
Neoplasm Metastasis
310
Leukemia, Myeloid, Acute
293
Colonic Neoplasms
283
Multiple Myeloma
281
Lymphoma
276
Esophageal Neoplasms
273
Uterine Cervical Neoplasms
272
Ovarian Neoplasms
263
Melanoma
246
Head and Neck Neoplasms
245
Precursor Cell Lymphoblastic Leukemia-Lymphoma
210
Brain Neoplasms
195
Lymphoma, Large B-Cell, Diffuse
187
Nasopharyngeal Carcinoma
182
Leukemia
173
Lymphoma, Non-Hodgkin
172
Liver Neoplasms
165
Glioblastoma
160
Polycystic Ovary Syndrome
157
Interventions
enzalutamide
1
capivasertib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Interventional
×
Adenocarcinoma of the Prostate
×
Clear all
NCT02525068
2018-08-08
RE-AKT
Institute of Cancer Research, United Kingdom
Phase 2
Unknown
136 enrolled